DDInter1961 DDInter1376
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Zidovudine {u} (Compound) resembles {v} (Compound) Idoxuridine
Zidovudine {u} (Compound) resembles {v} (Compound) Telbivudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Zidovudine {u} (Compound) binds {v} (Gene) UGT2B7
Zidovudine {u} (Compound) upregulates {v} (Gene) THAP11
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Reverse Transcriptase Inhibitors
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
Zidovudine {u} (Compound) causes {v} (Side Effect) Tremor
Zidovudine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Zidovudine (Compound) resembles Idoxuridine (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound)
Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease)
Zidovudine (Compound) binds UGT2B7 (Gene)
Zidovudine (Compound) upregulates THAP11 (Gene)
Zidovudine (Compound) is included by Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Zidovudine (Compound) downregulates MRPS16 (Gene)
Zidovudine (Compound) causes Tremor (Side Effect)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine